MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung...
3:59
MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung...
3 weeks ago
YouTubeecancer
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-Invasive...
6:00
Pembrolizumab alone achieves bladder preservation and ctDNA predicts outcomes in muscle-Invasive...
4 weeks ago
YouTubeecancer
Perioperative Immunotherapy Breakthrough
1:00
Perioperative Immunotherapy Breakthrough
74 views1 month ago
YouTubeBackTable ENT
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepat...
3:40
Adjuvant pembrolizumab fails to improve recurrence-free survival after curative therapy in hepat...
18 views4 weeks ago
YouTubeecancer
KEYNOTE-671: Neoadjuvant & Adjuvant Pembrolizumab in Early-Stage NSCLC – Phase 3 Trial Results.
7:16
KEYNOTE-671: Neoadjuvant & Adjuvant Pembrolizumab in Early-Stage NSCLC – Phase 3 Trial Results.
123 views11 months ago
YouTubeCancer Research and Statistic Foundation
HARMONi-2 Trial: Ivonescimab vs Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results (PL02.04)
12:07
HARMONi-2 Trial: Ivonescimab vs Pembrolizumab in PD-L1+ NSCLC | Phase 3 Results (PL02.04)
132 views11 months ago
YouTubeCancer Research and Statistic Foundation
Updates in EV-pembrolizumab MIBC from the KEYNOTE-905/EV-303 trial
3:34
Updates in EV-pembrolizumab MIBC from the KEYNOTE-905/EV-303 trial
165 views6 months ago
YouTubeVJOncology
7:32
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
146 views9 months ago
YouTubeecancer
1:24
SWOG S1801: 3-year outcomes of neoadjuvant-adjuvant pembrolizumab
120 views7 months ago
YouTubeVJOncology
9:53
NVALT-30 Trial (ESMO 2024): Low vs. Standard Dose Pembrolizumab in Stage IV NSCLC | 1258MO
10 views11 months ago
YouTubeCancer Research and Statistic Foundation
See more
Static thumbnail place holder